Secondary analysis of biopsies from 3 placebo-controlled trials in paediatric, adolescent and adult patients with eosinophilic esophagitis: dupilumab normalised the disease transcriptome, including 41 dysregulated biological processes, sustained to week 52.
Secondary analysis
Lim et al. Dupilumab normalizes the eosinophilic esophagitis disease transcriptome